S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:CRDF

Cardiff Oncology (CRDF) Stock Price, News & Analysis

$5.75
+0.36 (+6.68%)
(As of 03/27/2024 ET)
Today's Range
$5.31
$5.76
50-Day Range
$1.47
$5.91
52-Week Range
$0.94
$6.42
Volume
1.77 million shs
Average Volume
4.64 million shs
Market Capitalization
$256.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Cardiff Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
82.6% Upside
$10.50 Price Target
Short Interest
Bearish
6.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of Cardiff Oncology in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.98) to ($1.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.12 out of 5 stars

Medical Sector

854th out of 939 stocks

Biological Products, Except Diagnostic Industry

144th out of 154 stocks

CRDF stock logo

About Cardiff Oncology Stock (NASDAQ:CRDF)

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CRDF Stock Price History

CRDF Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
REGN Mar 2024 1010.000 put
REGN Mar 2024 982.500 call
CRDF Apr 2024 2.500 call
CRDF Nov 2024 10.000 put
CRDF Apr 2024 5.000 call
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
REGN Mar 2024 992.500 call
Q4 2023 Cardiff Oncology Inc Earnings Call
TD Cowen Sticks to Their Buy Rating for Cardiff Oncology (CRDF)
Cardiff Oncology Earnings Preview
See More Headlines
Receive CRDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CRDF
Fax
N/A
Employees
31
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$10.50
High Stock Price Target
$14.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+82.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-41,440,000.00
Net Margins
-8,492.01%
Pretax Margin
-8,492.01%

Debt

Sales & Book Value

Annual Sales
$490,000.00
Book Value
$1.56 per share

Miscellaneous

Free Float
41,862,000
Market Cap
$256.91 million
Optionable
Optionable
Beta
1.72

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

CRDF Stock Analysis - Frequently Asked Questions

Should I buy or sell Cardiff Oncology stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRDF shares.
View CRDF analyst ratings
or view top-rated stocks.

What is Cardiff Oncology's stock price target for 2024?

2 brokers have issued 1 year target prices for Cardiff Oncology's stock. Their CRDF share price targets range from $7.00 to $14.00. On average, they expect the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 82.6% from the stock's current price.
View analysts price targets for CRDF
or view top-rated stocks among Wall Street analysts.

How have CRDF shares performed in 2024?

Cardiff Oncology's stock was trading at $1.48 at the beginning of 2024. Since then, CRDF shares have increased by 288.5% and is now trading at $5.75.
View the best growth stocks for 2024 here
.

Are investors shorting Cardiff Oncology?

Cardiff Oncology saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,810,000 shares, an increase of 144.3% from the February 29th total of 1,150,000 shares. Based on an average daily volume of 1,540,000 shares, the days-to-cover ratio is presently 1.8 days.
View Cardiff Oncology's Short Interest
.

When is Cardiff Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CRDF earnings forecast
.

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:CRDF) announced its earnings results on Thursday, February, 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. The firm had revenue of $0.16 million for the quarter, compared to analysts' expectations of $0.08 million. Cardiff Oncology had a negative trailing twelve-month return on equity of 50.13% and a negative net margin of 8,492.01%.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA).

Who are Cardiff Oncology's major shareholders?

Cardiff Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.28%), Vanguard Group Inc. (4.28%), Creative Planning (0.06%), Virtu Financial LLC (0.05%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Gary W Pace, James E Levine, Lale White, Mark Erlander and Renee P Tannenbaum.
View institutional ownership trends
.

How do I buy shares of Cardiff Oncology?

Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRDF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners